Evidence map›Paper›PMID 24335889›Full record

ArticleBlood cancer journal2013

Alkylating agents induce histone H3K18 hyperacetylation and potentiate HDAC inhibitor-mediated global histone acetylation and cytotoxicity in mantle cell lymphoma.

N Hiraoka, J Kikuchi, D Koyama, T Wada, S Mori, Y Nakamura, Y Furukawa

Open access · goldAbstract read
In one paragraph

Article in Blood cancer journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Acetylation of Histone H3 in Cancer Progression and Prognosis.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Anticancer agents targeted to sirtuins.Molecules (Basel, Switzerland) · 2014
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

N HiraokaDivision of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
J KikuchiDivision of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
D KoyamaDivision of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
T WadaDivision of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
S MoriMedical Education Center, Saitama Medical University, Saitama, Japan.
Y NakamuraDepartment of Hematology, Saitama Medical University, Saitama, Japan.
Y FurukawaDivision of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Tochigi, Japan.
Jichi Medical University · JPSaitama Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID24335889
PMCPMC3877423
OpenAlexW2010426744

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.